Literature DB >> 14668716

The role of human achaete-scute homolog-1 in medullary thyroid cancer cells.

Rebecca S Sippel1, Jennifer E Carpenter, Muthusamy Kunnimalaiyaan, Herbert Chen.   

Abstract

BACKGROUND: Human achaete-scute homolog-1 (hASH1) is a transcription factor that is expressed highly in neuroendocrine tumors such as medullary thyroid cancer (MTC). Thyroid C-cells do not develop in hASH1 knockout mice, which suggests that hASH1 is essential for normal C-cell development.
METHODS: To determine the effect of raf-1 induction on hASH1 and hormone production, we used an estrogen inducible raf-1 construct in MTC cell line (TT) cells (TT-raf cells). TT or TT-raf cells were treated with control or 1 microM estradiol. After 48 hours, the cells were analyzed for levels of hASH1 and chromogranin A by Western blotting and for calcitonin production by enzyme-linked immunosorbent assay.
RESULTS: Activation of raf-1 in the TT-raf cells resulted in high levels of phosphorylated MEK and ERK1/2, a morphologic transdifferentiation, and a decrease in chromogranin A and calcitonin levels that are associated with a reduction in hASH1 production. Furthermore, using MEK inhibitors, we demonstrated that these raf-1-mediated changes are dependent on MEK but not ERK1/2 activation.
CONCLUSION: hASH1 down-regulation by raf-1 in MTC cells is associated with a significant decrease in hormone production. Thus, hASH1 appears to be important in the endocrine phenotype of MTC tumors and may serve as a molecular target for the treatment of patients with MTC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668716     DOI: 10.1016/s0039-6060(03)00418-5

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  30 in total

1.  Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.

Authors:  Matthew Truong; Mackenzie R Cook; Scott N Pinchot; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2010-12-24       Impact factor: 5.344

Review 2.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

3.  Inhibition of the PI3K pathway suppresses hormonal secretion and limits growth in pheochromocytoma cells.

Authors:  Joel T Adler; Daniel G Hottinger; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

4.  Expression of the active Notch1 decreases MTC tumor growth in vivo.

Authors:  Renata Jaskula-Sztul; Pongthep Pisarnturakit; Michael Landowski; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  J Surg Res       Date:  2011-04-13       Impact factor: 2.192

Review 5.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

6.  Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway.

Authors:  Li Ning; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

7.  Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.

Authors:  Yash Somnay; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Neuroendocrinology       Date:  2012-09-04       Impact factor: 4.914

Review 8.  The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer.

Authors:  Susan C Pitt; Herbert Chen
Journal:  Surgery       Date:  2008-09-03       Impact factor: 3.982

9.  Valproic acid induces Notch1 signaling in small cell lung cancer cells.

Authors:  Christopher S Platta; David Yü Greenblatt; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Surg Res       Date:  2008-04-10       Impact factor: 2.192

10.  Medullary thyroid carcinoma: targeted therapies and future directions.

Authors:  Scott N Pinchot; Muthusamy Kunnimalaiyaan; Rebecca S Sippel; Herbert Chen
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.